Literature DB >> 20606095

Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?

Arnie Purushotham1, Sarah Pinder, Massi Cariati, Mark Harries, Aron Goldhirsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20606095     DOI： 10.1200/JCO.2009.27.8184

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

Review 1.  Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer.

Authors:  Heather C Bruner; Patrick W B Derksen
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-03-01       Impact factor: 10.005

Review 2.  Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?

Authors:  Philippe L Bedard; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

3.  Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Authors:  Esther H Lips; Rita A Mukhtar; Christina Yau; Jorma J de Ronde; Chad Livasy; Lisa A Carey; Claudette E Loo; Marie-Jeanne T F D Vrancken-Peeters; Gabe S Sonke; Donald A Berry; Laura J Van't Veer; Laura J Esserman; Jelle Wesseling; Sjoerd Rodenhuis; E Shelley Hwang
Journal:  Breast Cancer Res Treat       Date:  2012-09-08       Impact factor: 4.872

4.  Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.

Authors:  Y Delpech; C Coutant; L Hsu; E Barranger; T Iwamoto; C H Barcenas; G N Hortobagyi; R Rouzier; F J Esteva; L Pusztai
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

5.  Review of breast conservation therapy: then and now.

Authors:  Susan Hoover; Elizabeth Bloom; Sunil Patel
Journal:  ISRN Oncol       Date:  2011-09-12

6.  Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.

Authors:  Wilfred Truin; Rudi M H Roumen; Sabine Siesling; Koen K van de Vijver; Vivianne C G Tjan-Heijnen; Adri C Voogd
Journal:  Breast Cancer Res Treat       Date:  2017-04-01       Impact factor: 4.872

7.  Making progress in early breast cancer: Taking time or accepting risk?

Authors:  Gurdeep S Mannu; David Dodwell
Journal:  Eur J Cancer       Date:  2017-04-12       Impact factor: 9.162

8.  The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.

Authors:  Dorien Lobbezoo; Wilfred Truin; Adri Voogd; Rudi Roumen; Gerard Vreugdenhil; Marcus Wouter Dercksen; Franchette van den Berkmortel; Tineke Smilde; Agnes van de Wouw; Roel van Kampen; Johanna van Riel; Natascha Peters; Petronella Peer; Vivianne C G Tjan-Heijnen
Journal:  Oncotarget       Date:  2016-05-17

9.  Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.

Authors:  Guangfu Hu; Guangxia Hu; Chengjiao Zhang; Xiaoyan Lin; Ming Shan; Yanmin Yu; Yongwei Lu; Ruijie Niu; Hui Ye; Cheng Wang; Cheng Xu
Journal:  BMC Cancer       Date:  2020-02-21       Impact factor: 4.430

10.  Breast Cancer in the United States: A Cross-Sectional Overview.

Authors:  Nadeem Bilani; Emily C Zabor; Leah Elson; Elizabeth B Elimimian; Zeina Nahleh
Journal:  J Cancer Epidemiol       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.